|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-9-20
|
|
pubmed:abstractText |
Myelodysplastic syndromes (MDS) are a heterogeneous group of hemopoietic progenitor cell disorders, and patients with MDS regularly develop anemia and frequently become transfusion-dependent. Treatment with erythropoietin (EPO) has been tried to correct anemia with only limited success with response rates ranging from 16% to 25%. However, it is becoming evident that the generally rather low response rate of EPO in patients with MDS will be improved by the combination of EPO with either G-CSF or GM-CSF.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0171-5216
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
497-502
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
|
|
pubmed:affiliation |
Department of Medicine II (Oncology-Hematology-Endocrinology), Friedrich-Schiller-University Jena, 07740 Jena, Germany. christoph.kasper@med.uni-jena.de
|
|
pubmed:publicationType |
Journal Article,
Meta-Analysis
|
